Pamela Munster
University of California, San Francisco
H-index: 69
North America-United States
Top articles of Pamela Munster
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Drug Implants Containing Apalutamide and Methods of Use Thereof | 2024/1/18 | ||
Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors | International Journal of Cancer Care and Delivery | Sibapriya Chaudhuri Scott Thomas Luika Timmerman Pamela Munster | 2023/12/6 |
Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human … | Cancer Research | Sara Hurvitz Anne Schott Cynthia Ma Rita Nanda George Zahrah | 2024/5/2 |
Drug Implants Containing Darolutamide and Methods of Use Thereof | 2024/2/1 | ||
PD13-10 A PHASE 1 SAFETY, PK AND PRELIMINARY EFFICACY STUDY OF LOCALIZED THERAPY USING BIOLEN (BICALUTAMIDE) IMPLANTS FOR EARLY-STAGE PROSTATE CANCER | The Journal of Urology | Alexander Kenigsberg Henry Woo Mark Fraundorfer Janelle Brennan Peter Chin | 2024/5 |
Abstract B019: Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors | Cancer Research | Sibapriya Chaudhuri Scott Thomas Luika Timmerman Pamela Munster | 2024/2/1 |
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors | Cancer Research Communications | Mark Yarchoan John D Powderly Bruno R Bastos Thomas B Karasic Oxana V Crysler | 2024/4/18 |
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies | Clinical Cancer Research | Benedito A Carneiro Ludimila Cavalcante Devalingam Mahalingam Anwaar Saeed Howard Safran | 2024/2/1 |
Implantable Drug Delivery Devices For Localized Drug Delivery | 2024/3/28 | ||
Abstract PO1-20-04: STX-478-101: A phase 1/2, first-in-human study of STX-478 monotherapy or in combination with fulvestrant in patients with breast cancer or other advanced … | Cancer Research | Alberto Montero Douglas Orr Pamela Munster Patricia LoRusso Komal Jhaveri | 2024/5/2 |
First-in-human evaluation of a prostate-specific membrane antigen–targeted near-infrared fluorescent small molecule for fluorescence-based identification of prostate cancer in … | European Urology Oncology | Hao G Nguyen Nynke S van den Berg Alexander L Antaris Lingru Xue Scott Greenberg | 2024/2/1 |
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study | Cancer Research Communications | Pamela Munster Nicholas Iannotti Daniel C Cho John M Kirkwood Liza C Villaruz | 2024/3/13 |
Abstract RF02-05: Report on Cohort Expansion of Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with … | Cancer Research | Fei Ma Pamela Munster Xiaoxiang Guan Jingfen Wang Herui Yao | 2024/5/2 |
A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models | Research Square | Scott Thomas Elysia Roche Pujan Desai Nela Pawlowska Diana Bauer | 2023/10/23 |
Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase … | Cancer Research | Anne F Schott Sara Hurvitz Cynthia Ma Erika Hamilton Rita Nanda | 2023/3/1 |
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer—Turning an Old Foe Into a Friend? | JAMA oncology | Erica S Tsang Pamela N Munster | 2023/7/1 |
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2 … | ESMO Open | SA Hurvitz A Schott CX Ma R Nanda G Zahrah | 2023/5/1 |
550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study | Annals of Oncology | RH Xu Y Xu D Yan P Munster D Ruan | 2023/10/1 |
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study | Cancer Research Communications | Pamela Munster Nicholas Iannotti Daniel C Cho John M Kirkwood Liza C Villaruz | 2023/12/19 |
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001). | Aaron Scott Mansfield Austin Goodrich Nathan R Foster Panos Savvides Liza C Villaruz | 2023/6/1 |
Co-Authors
